1. Home
  2. LUNG vs AQST Comparison

LUNG vs AQST Comparison

Compare LUNG & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.59

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

HOLD

Current Price

$5.79

Market Cap

809.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUNG
AQST
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
809.3M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
LUNG
AQST
Price
$2.59
$5.79
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$6.81
$8.83
AVG Volume (30 Days)
1.1M
2.3M
Earning Date
11-12-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$91,664,000.00
$43,397,000.00
Revenue This Year
$9.21
N/A
Revenue Next Year
$5.03
$52.69
P/E Ratio
N/A
N/A
Revenue Growth
15.59
N/A
52 Week Low
$1.31
$2.12
52 Week High
$9.37
$7.55

Technical Indicators

Market Signals
Indicator
LUNG
AQST
Relative Strength Index (RSI) 69.75 44.66
Support Level $2.43 $5.61
Resistance Level $2.65 $6.44
Average True Range (ATR) 0.21 0.31
MACD 0.05 -0.05
Stochastic Oscillator 92.13 16.00

Price Performance

Historical Comparison
LUNG
AQST

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Share on Social Networks: